BACKGROUND: Several non-motor features have been reported to precede the motor signs of Parkinson's disease (PD) by several years. However, the time of onset of non-motor and motor symptoms is still debated. Healthy individuals carrying a PD-related mutation are candidates for studying the earliest disease signs. OBJECTIVES: To describe clinically healthy family members of PD patients carrying a LRRK2 mutation (LRRK2-PD). METHODS: A total of 47 family members of LRRK2-PD patients were included in the present study and were screened for the p.G2019S and p.N1437H substitutions in the LRRK2 gene. A standardized case report form was filled out in each case, including general medical evaluation, neurological examination with UPDRS, an olfaction test, mood, sleep and cognitive questionnaires. RESULTS: Thirty-two study participants were positive, and 15 were negative for a LRRK2 mutation. Higher UPDRS motor scores, more frequent reports of urinary problems, and fewer hours of sleep were found in mutation carriers compared to non-carriers. The mutation carriers with UPDRS ≥8 were all aged over 50 years, had shorter overall sleeping hours, more frequent urinary and constipation problems, higher mood scores and body mass index. Deterioration of olfaction was not detected in either group. CONCLUSION: Healthy LRRK2 mutation carriers presented subclinical parkinsonian motor and non-motor signs in the apparent absence of olfactory loss. Longitudinal studies will determine whether these changes precede alterations detectable by neuroimaging.
BACKGROUND: Several non-motor features have been reported to precede the motor signs of Parkinson's disease (PD) by several years. However, the time of onset of non-motor and motor symptoms is still debated. Healthy individuals carrying a PD-related mutation are candidates for studying the earliest disease signs. OBJECTIVES: To describe clinically healthy family members of PDpatients carrying a LRRK2 mutation (LRRK2-PD). METHODS: A total of 47 family members of LRRK2-PDpatients were included in the present study and were screened for the p.G2019S and p.N1437H substitutions in the LRRK2 gene. A standardized case report form was filled out in each case, including general medical evaluation, neurological examination with UPDRS, an olfaction test, mood, sleep and cognitive questionnaires. RESULTS: Thirty-two study participants were positive, and 15 were negative for a LRRK2 mutation. Higher UPDRS motor scores, more frequent reports of urinary problems, and fewer hours of sleep were found in mutation carriers compared to non-carriers. The mutation carriers with UPDRS ≥8 were all aged over 50 years, had shorter overall sleeping hours, more frequent urinary and constipation problems, higher mood scores and body mass index. Deterioration of olfaction was not detected in either group. CONCLUSION: Healthy LRRK2 mutation carriers presented subclinical parkinsonian motor and non-motor signs in the apparent absence of olfactory loss. Longitudinal studies will determine whether these changes precede alterations detectable by neuroimaging.
Authors: Andreas Puschmann; Elisabet Englund; Owen A Ross; Carles Vilariño-Güell; Sarah J Lincoln; Jennifer M Kachergus; Stephanie A Cobb; Anna-Lena Törnqvist; Stig Rehncrona; Håkan Widner; Zbigniew K Wszolek; Matthew J Farrer; Christer Nilsson Journal: Parkinsonism Relat Disord Date: 2011-12-06 Impact factor: 4.891
Authors: Claustre Pont-Sunyer; Alex Iranzo; Carles Gaig; Ana Fernández-Arcos; Dolores Vilas; Francesc Valldeoriola; Yaroslau Compta; Ruben Fernández-Santiago; Manel Fernández; Angels Bayés; Matilde Calopa; Pilar Casquero; Oriol de Fàbregues; Serge Jaumà; Victor Puente; Manel Salamero; Maria José Martí; Joan Santamaría; Eduard Tolosa Journal: PLoS One Date: 2015-07-15 Impact factor: 3.240
Authors: Jan O Aasly; Krisztina K Johansen; Gunnar Brønstad; Bjørg J Warø; Nour K Majbour; Shiji Varghese; Fatimah Alzahmi; Katerina E Paleologou; Dena A M Amer; Abdulmonem Al-Hayani; Omar M A El-Agnaf Journal: Front Aging Neurosci Date: 2014-09-25 Impact factor: 5.750
Authors: Nour K Majbour; Jan O Aasly; Eldbjørg Hustad; Mercy A Thomas; Nishant N Vaikath; Naser Elkum; Wilma D J van de Berg; Takahiko Tokuda; Brit Mollenhauer; Henk W Berendse; Omar M A El-Agnaf Journal: Transl Neurodegener Date: 2020-05-06 Impact factor: 8.014